Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/798
| Subject | Predicate | Object | Context |
|---|---|---|---|
| dailymed-drugs:798 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:798 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:798 | rdfs:label | Simvastatin (Tablet, Orally Disintegrating) | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:dosage | The patient should be placed on a standard cholesterol-lowering diet. In patients with CHD or at high risk of CHD, Simvastatin Orally Disintegrating Tablets can be started simultaneously with diet. The dosage should be individualized according to the goals of therapy and the patient's response. The dosage range is 5-80 mg/day (see below). The recommended usual starting dose is 20 to 40 mg once a day in the evening. For patients at high risk for a CHD event due to existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, the recommended starting dose is 40 mg/day. The orally disintegrating tablet should be placed on the tongue where it will dissolve and then be swallowed with the saliva. If necessary, follow with water. Lipid determinations should be performed after 4 weeks of therapy and periodically thereafter. See below for dosage recommendations in special populations (i.e., homozygous familial hypercholesterolemia, adolescents and renal insufficiency) or for patients receiving concomitant therapy (i.e., cyclosporine, danazol, amiodarone, verapamil, or gemfibrozil).<br/>Patients with Homozygous Familial Hypercholesterolemia: The recommended dosage for patients with homozygous familial hypercholesterolemia is Simvastatin Orally Disintegrating Tablets 40 mg/day in the evening or 80 mg/day in 3 divided doses of 20 mg, 20 mg, and an evening dose of 40 mg. Simvastatin Orally Disintegrating Tablets should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.<br/>Adolescents (10-17 years of age) with Heterozygous Familial Hypercholesterolemia: The recommended usual starting dose is 10 mg once a day in the evening. The recommended dosing range is 10-40 mg/day; the maximum recommended dose is 40 mg/day. Doses should be individualized according to the recommended goal of therapy (see NCEP Pediatric Panel Guidelinesand CLINICAL PHARMACOLOGY). Adjustments should be made at intervals of 4 weeks or more.<br/>Concomitant Lipid-Lowering Therapy: Simvastatin Orally Disintegrating Tablets are effective alone or when used concomitantly with bile-acid sequestrants. If Simvastatin Orally Disintegrating Tablets are used in combination with gemfibrozil, the dose of Simvastatin Orally Disintegrating Tablets should not exceed 10 mg/day .<br/>Patients taking Cyclosporine or Danazol: In patients taking cyclosporine or danazol concomitantly with Simvastatin Orally Disintegrating Tablets , therapy should begin with 5 mg/day and should not exceed 10 mg/day. Simvastatin Orally Disintegrating Tablets are not available in the 5 mg dosage strength. Other simvastatin 5 mg tablets should be used if a 5 mg dose is needed.<br/>Patients taking Amiodarone or Verapamil: In patients taking amiodarone or verapamil concomitantly with Simvastatin Orally Disintegrating Tablets, the dose should not exceed 20 mg/day .<br/>Patients with Renal Insufficiency: Because Simvastatin Orally Disintegrating Tablets do not undergo significant renal excretion, modification of dosage should not be necessary in patients with mild to moderate renal insufficiency. However, caution should be exercised when Simvastatin Orally Disintegrating Tablets are administered to patients with severe renal insufficiency; such patients should be started at 5 mg/day and be closely monitored . Simvastatin Orally Disintegrating Tablets are not available in the 5 mg dosage strength. Other simvastatin 5 mg tablets should be used if a 5 mg dose is needed.<br/>Administration of Simvastatin Orally Disintegrating Tablets: Place the orally disintegrating tablet on the tongue where it will dissolve and then be swallowed with the saliva. If necessary, follow with water. | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:descripti... | Simvastatin is a lipid-lowering agent that is derived synthetically from a fermentation product of Aspergillus terreus. After oral ingestion, simvastatin, which is an inactive lactone, is hydrolyzed to the corresponding��-hydroxyacid form. This is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate-limiting step in the biosynthesis of cholesterol. Simvastatin is butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1��,3��,7��,8��(2S*,4S*),-8a��]]. The empirical formula of simvastatin is CHOand its molecular weight is 418.57. Its structural formula is: Simvastatin is a white to off-white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol. Simvastatin Orally Disintegrating Tablets for oral administration contain either 10 mg, 20 mg, 40 mg or 80 mg of simvastatin. The tablets begin disintegrating in the mouth within seconds, allowing its contents to be subsequently swallowed. Simvastatin Orally Disintegrating Tablets also contain the following inactive ingredients: crospovidone, glyceryl behenate, hydroxypropyl cellulose, iron oxide yellow (10 mg and 20 mg tablets only), iron oxide red (20 mg and 40 mg tablets only), mint menthol, povidone, silicified microcrystalline cellulose, and sucralose. Butylated hydroxyanisole is added as an preservative. | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:clinicalP... | Epidemiological studies have demonstrated that elevated levels of total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), as well as decreased levels of high-density lipoprotein cholesterol (HDL-C) are associated with the development of atherosclerosis and increased cardiovascular risk. Lowering LDL-C decreases this risk. However, the independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.<br/>Pharmacokinetics: Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding��-hydroxyacid, a potent inhibitor of HMG-CoA reductase. Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the��-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin. The pharmacokinetics of simvastatin and simvastatin acid, following administration of the 80 mg Simvastatin Orally Disintegrating tablet and 240 mL water at 1 minute post-dosing, were comparable to those following administration of the simvastatin immediate release 80 mg tablet taken with 240 mL water. Following an oral dose ofC-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces. Plasma concentrations of total radioactivity (simvastatin plusC-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose. Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of the drug to the general circulation is low (<5%). Both simvastatin and its��-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins. Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier. The major active metabolites of simvastatin present in human plasma are the��-hydroxyacid of simvastatin and its 6���-hydroxy, 6���-hydroxymethyl, and 6���-exomethylene derivatives. Peak plasma concentrations of both active and total inhibitors were attained within 1.3 to 2.4 hours postdose. While the recommended therapeutic dose range is 5 to 80 mg/day, there was no substantial deviation from linearity of AUC of inhibitors in the general circulation with an increase in dose to as high as 120 mg. Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatinwas administered immediately before an American Heart Association recommended low-fat meal. In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age. Clinical study experience in the elderly (n=1522), suggests that there were no overall differences in safety between elderly and younger patients . Kinetic studies with another reductase inhibitor, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance). In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin. This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4. Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of HMG-CoA reductase inhibitors. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4. The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma. Potent inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy . Gemfibrozil: Coadministration of gemfibrozil (600 mg twice daily for 3 days) with simvastatin (40 mg daily) resulted in clinically significant increases in simvastatin acid AUC (185%) and Cmax (112%), possibly due to inhibition of simvastatin acid glucuronidation by gemfibrozil . Fenofibrate: Coadministration of fenofibrate (160 mg daily) with simvastatin (80 mg daily) for 7 days had no effect on plasma AUC (and Cmax) of either total HMG-CoA reductase inhibitory activity or fenofibric acid; there was a modest reduction (approximately 35%) of simvastatin acid which was not considered clinically significant . Simvastatin is a substrate for CYP3A4 . Grapefruit juice contains one or more components that inhibit CYP3A4 and can increase the plasma concentrations of drugs metabolized by CYP3A4. In one study, 10 subjects consumed 200 mL of double-strength grapefruit juice (one can of frozen concentrate diluted with one rather than 3 cans of water) three times daily for 2 days and an additional 200 mL double-strength grapefruit juice together with, and 30 and 90 minutes following, a single dose of 60 mg simvastatin on the third day. This regimen of grapefruit juice resulted in mean increases in the concentration (as measured by the area under the concentration-time curve) of active and total HMG-CoA reductase inhibitory activity [measured using a radioenzyme inhibition assay both before (for active inhibitors) and after (for total inhibitors) base hydrolysis] of 2.4-fold and 3.6-fold, respectively, and of simvastatin and its��-hydroxyacid metabolite [measured using a chemical assay���liquid chromatography/tandem mass spectrometry] of 16-fold and 7-fold, respectively. In a second study, 16 subjects consumed one 8 oz glass of single-strength grapefruit juice (one can of frozen concentrate diluted with 3 cans of water) with breakfast for 3 consecutive days and a single dose of 20 mg simvastatin in the evening of the third day. This regimen of grapefruit juice resulted in a mean increase in the plasma concentration (as measured by the area under the concentration-time curve) of active and total HMG-CoA reductase inhibitory activity [using a validated enzyme inhibition assay different from that used in the firststudy, both before (for active inhibitors) and after (for total inhibitors) base hydrolysis] of 1.13-fold and 1.18-fold, respectively, and of simvastatin and its��-hydroxyacid metabolite [measured using a chemical assay���liquid chromatography/tandem mass spectrometry] of 1.88-fold and 1.31-fold, respectively. The effect of amounts of grapefruit juice between those used in these two studies on simvastatin pharmacokinetics has not been studied.<br/>Clinical Studies in Adults:<br/>Reductions in Risk of CHD Mortality and Cardiovascular Events: In 4S, the effect of therapy with simvastatin on total mortality was assessed in 4,444 patients with CHD and baseline total cholesterol 212-309 mg/dL (5.5-8.0 mmol/L). In this multicenter, randomized, double-blind, placebo-controlled study, patients were treated with standard care, including diet, and either simvastatin 20-40 mg/day (n=2,221) or placebo (n=2,223) for a median duration of 5.4 years. After six weeks of treatment with simvastatin the median (25and 75percentile) changes in LDL-C, TG, and HDL-C were -39% (-46, -31%), -19% (-31, 0%), and 6% (-3, 17%). Over the course of the study, treatment with simvastatin led to mean reductions in total-C, LDL-C and TG of 25%, 35%, and 10%, respectively, and a mean increase in HDL-C of 8%. Simvastatin significantly reduced the risk of mortality by 30% (p=0.0003, 182 deaths in the simvastatin group vs 256 deaths in theplacebo group). The risk of CHD mortality was significantly reduced by 42% (p=0.00001, 111 vs 189 deaths). There was no statistically significant difference between groups in non-cardiovascular mortality. Simvastatin also significantly decreased the risk of having major coronary events (CHD mortality plus hospital-verified and silent non-fatal myocardial infarction [MI]) by 34% (p<0.00001, 431 vs 622 patients with one or more events). The risk of having a hospital-verified non-fatal MI was reduced by 37%. Simvastatin significantly reduced the risk for undergoing myocardial revascularization procedures (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty) by 37% (p<0.00001, 252 vs 383 patients). Furthermore, simvastatin significantly reduced the risk of fatal plus non-fatal cerebrovascular events (combined stroke and transient ischemic attacks) by 28% (p=0.033, 75 vs 102 patients). Simvastatin reduced the risk of major coronary events to a similar extent across the range of baseline total and LDL cholesterol levels. Because there were only 53 female deaths, the effect of simvastatin on mortality in women could not be adequately assessed. However, simvastatin significantly lessened the risk of having major coronary events by 34% (60 vs 91 women with one or more event). The randomization was stratified by angina alone (21% of each treatment group) or a previous MI. Because there were only 57 deaths among the patients with angina alone at baseline, the effect of simvastatin onmortality in this subgroup could not be adequately assessed. However, trends in reduced coronary mortality, major coronary events and revascularization procedures were consistent between this group and the total study cohort. Additionally, in this study, 1,021 of the patients were 65 and older. Cholesterol reduction with simvastatin resulted in similar decreases in relative risk for total mortality, CHD mortality, and major coronary events in these elderly patients, compared with younger patients. The Heart Protection Study (HPS) was a large, multi-center, placebo-controlled, double-blind study with a mean duration of 5 years conducted in 20,536 patients (10,269 on simvastatin 40 mg and 10,267 on placebo). Patients were allocated to treatment using a covariate adaptive methodwhich took into account the distribution of 10 important baseline characteristics of patients already enrolled and minimized the imbalance of those characteristics across the groups. Patients had a mean age of 64 years (range 40-80 years), were 97% Caucasian and were at high risk of developing a major coronary event because of existing coronary heart disease (65%), diabetes (Type 2, 26%; Type 1, 3%), history of stroke or other cerebrovascular disease (16%), peripheral vessel disease (33%), or hypertension in males 65 years of age and older (6%). At baseline, 3,421 patients (17%) had LDL-C levels below 100 mg/dL, of whom 953 (5%) had LDL-C levels below 80 mg/dL; 7,068 patients (34%) had levels between 100 and 130 mg/dL; and 10,047 patients (49%) had levels greater than 130 mg/dL. The HPS results showed that simvastatin 40 mg/day significantly reduced: total and CHD mortality; nonfatal myocardial infarctions, stroke, and revascularization procedures (coronary and non-coronary) (see Table 1). Two composite endpoints were defined in order to have sufficient events to assess relative risk reductions across a range of baseline characteristics (see Figure 1). A composite of major coronary events (MCE) was comprised of CHD mortality and non-fatal MI (analyzed by time-to-first event; 898 patients treated with simvastatin had events and 1,212 patients on placebo had events). A composite of major vascular events (MVE) was comprised of MCE, stroke and revascularization procedures including coronary, peripheral and other non-coronary procedures (analyzed by time-to-first event; 2,033 patients treated with simvastatin had events and 2,585 patients on placebo had events). Significant relative risk reductions were observed for both composite endpoints (27% for MCE and 24% for MVE, p<0.0001). Furthermore, treatment with simvastatin produced significant relative risk reductions for all components of the composite endpoints. The risk reductions produced by simvastatin in both MCE and MVE were evident and consistent regardless of cardiovascular disease related medical history at study entry (i.e., CHD alone; or peripheral vascular disease, cerebrovascular disease, diabetes or treated hypertension, with or without CHD), gender, age, creatinine levels up to the entry limit of 2.3 mg/dL, baseline levels of LDL-C, HDL-C, apolipoprotein B and A-1, baseline concomitant cardiovascular medications (i.e., aspirin, beta blockers, or calcium channel blockers), smoking status, alcohol intake, or obesity. Diabetics showed risk reductions for MCE and MVE due to simvastatin treatment regardless of baseline HbA1c levels or obesity with the greatest effects seen for diabetics without CHD.<br/>Angiographic Studies: In the Multicenter Anti-Atheroma Study, the effect of simvastatin on atherosclerosis was assessed by quantitative coronary angiography in hypercholesterolemic patients with coronary heart disease. In this randomized, double-blind, controlled study, patients were treated with simvastatin 20 mg/day or placebo. Angiograms were evaluated at baseline, two and four years. The co-primary study endpoints were mean change per-patient in minimum and mean lumen diameters, indicating focal and diffuse disease, respectively. Simvastatin significantly slowed the progression of lesions as measured in the Year 4 angiogram by both parameters, as well as by change in percent diameter stenosis. In addition, simvastatin significantly decreased the proportion of patients with new lesions and with new total occlusions.<br/>Modifications of Lipid Profiles:<br/>Clinical Studies in Adolescents: In a double-blind, placebo-controlled study, 175 patients (99 adolescent boys and 76 post-menarchal girls) 10-17 years of age (mean age 14.1 years) with heterozygous familial hypercholesterolemia (heFH) were randomized to simvastatin (n=106) or placebo (n=67) for 24 weeks (base study). Inclusion in the study required a baseline LDL-C level between 160 and 400mg/dL and at least one parent with an LDL-C level>189 mg/dL. The dosage of simvastatin (once daily in the evening) was 10 mg for the first 8 weeks, 20 mg for the second 8 weeks, and 40 mg thereafter. In a 24-week extension, 144 patients elected to continue therapy and received simvastatin 40 mg or placebo. Simvastatin significantly decreased plasma levels of total-C, LDL-C, and Apo B (see Table 5). Results from the extension at 48 weeks were comparable to those observed in the base study. After 24 weeks of treatment, the mean achieved LDL-C value was 124.9 mg/dL (range: 64.0-289.0 mg/dL) in the simvastatin 40 mg group compared to 207.8 mg/dL (range: 128.0-334.0 mg/dL) in the placebo group. The safety and efficacy of doses above 40 mg daily have not been studied in children with heterozygous familial hypercholesterolemia. The long-term efficacy of simvastatin therapy in childhood to reduce morbidity and mortality in adulthood has not been established. | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:activeIng... | dailymed-ingredient:Simvast... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:supply | Simvastatin Orally Disintegrating Tablets 10 mg are yellow, round, biconvex tablets with S10 debossed on one side and ODT on the other side. They are supplied as follows: NDC 63672-0001-1, Bottles of 30NDC 63672-0001-3, Bottles of 90 Simvastatin Orally Disintegrating Tablets 20 mg are peach, round, biconvex tablets with S20 debossed on one side and ODT on the other side. They are supplied as follows: NDC 63672-0002-1, Bottles of 30NDC 63672-0002-3, Bottles of 90 Simvastatin Orally Disintegrating Tablets 40 mg are pink, round, biconvex tablets with S40 debossed on one side and ODT on the other side. They are supplied as follows: NDC 63672-0003-1, Bottles of 30NDC 63672-0003-3, Bottles of 90 Simvastatin Orally Disintegrating Tablets 80 mg are white, round, biconvex tablets with S80 debossed on one side and ODT on the other side. They are supplied as follows: NDC 63672-0004-1, Bottles of 30NDC 63672-0004-3, Bottles of 90 Store bottles at controlled room temperature, 20��to 25��C (68��to 77��F). Excursions permitted to 15��to 30��C (59��to 86��F). See USP Controlled Room Temperature. | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:genericDr... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:activeMoi... | dailymed-ingredient:Simvast... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:hydroxy... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:povidon... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:crospov... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:iron_ox... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:iron_ox... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:cellulo... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:sucralo... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:glycery... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:mint_me... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:silicif... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:inactiveI... | dailymed-ingredient:butylat... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:116 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:764 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:634 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2839 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:319 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2175 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:561 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:1283 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:1092 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:3977 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:949 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2701 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:3639 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:3730 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:51 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:710 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:307 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:1043 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:1507 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2129 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:3045 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:3166 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:3867 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:270 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:102 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:345 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:535 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:560 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:592 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:604 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:674 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:1154 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:1155 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:1368 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:1471 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2010 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2210 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2652 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2695 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2760 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2794 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:2951 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:3044 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:4095 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:possibleD... | diseasome-diseases:4097 | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:overdosag... | Significant lethality was observed in mice after a single oral dose of 9 g/m. No evidence of lethality was observed in rats or dogs treated with doses of 30 and 100 g/m, respectively. No specific diagnostic signs were observed in rodents. At these doses the only signs seen in dogs were emesis and mucoid stools. A few cases of overdosage with simvastatin have been reported; the maximum dose taken was 3.6 g. All patients recovered without sequelae. Until further experience is obtained, no specific treatment of overdosage with simvastatin can be recommended. The dialyzability of simvastatin and its metabolites in man is not known at present. | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:genericMe... | Simvastatin | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:fullName | Simvastatin (Tablet, Orally Disintegrating) | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:adverseRe... | In the pre-marketing controlled clinical studies and their open extensions (2,423 patients with mean duration of follow-up of approximately 18 months), 1.4% of patients were discontinued due to adverse experiences attributable to simvastatin. Adverse reactions have usually been mild and transient. Simvastatin has been evaluated for serious adverse reactions in more than 21,000 patients and is generally well tolerated.<br/>Clinical Adverse ExperiencesIn Adults: Adverse experiences occurring in adults at an incidence of 1% or greater in patients treated with simvastatin, regardless of causality, in controlled clinical studies are shown in Table 9.<br/>Scandinavian Simvastatin Survival StudyClinical Adverse Experiences: In 4S involving 4,444 patients treated with 20-40 mg/day of simvastatin (n=2,221) or placebo (n=2,223), the safety and tolerability profiles were comparable between groups over the median 5.4 years of the study. The clinical adverse experiences reported as possibly, probably, or definitely drug-related in���0.5% in either treatment group are shown in Table 10.<br/>Heart Protection StudyClinical Adverse Experiences: In HPS , involving 20,536 patients treated with simvastatin 40 mg/day (n=10,269) or placebo (n=10,267), the safety profiles were comparable between patients treated with simvastatin and patients treated with placebo over the mean 5 years of the study. In this large trial, only serious adverse events and discontinuations due to any adverse events were recorded. Discontinuation rates due to adverse experiences were comparable (4.8% in patients treated with simvastatin compared with 5.1% in patients treated with placebo). The incidence of myopathy/rhabdomyolysis was<0.1% in patients treated with simvastatin. The following effects have been reported with drugs in this class. Not all the effects listed below have necessarily been associated with simvastatin therapy. Skeletal: muscle cramps, myalgia, myopathy, rhabdomyolysis, arthralgias. Neurological: dysfunction of certain cranial nerves (including alteration of taste, impairment of extra-ocular movement, facial paresis), tremor, dizziness, vertigo, memory loss, paresthesia, peripheral neuropathy, peripheral nerve palsy, psychic disturbances, anxiety, insomnia, depression. Hypersensitivity Reactions: An apparent hypersensitivity syndrome has been reported rarely which has included one or more of the following features: anaphylaxis, angioedema, lupus erythematous-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, purpura, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, arthralgia, urticaria, asthenia, photosensitivity, fever, chills, flushing, malaise, dyspnea, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome. Gastrointestinal: pancreatitis, hepatitis, including chronic active hepatitis, cholestatic jaundice, fatty change in liver, and, rarely, cirrhosis, fulminant hepatic necrosis, and hepatoma; anorexia, vomiting. Skin: alopecia, pruritus. A variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails) have been reported. Reproductive: gynecomastia, loss of libido, erectile dysfunction. Eye: progression of cataracts (lens opacities), ophthalmoplegia. Laboratory Abnormalities: elevated transaminases, alkaline phosphatase,��-glutamyl transpeptidase, and bilirubin; thyroid function abnormalities.<br/>Laboratory Tests: Marked persistent increases of serum transaminases have been noted . About 5% of patients had elevations of CK levels of 3 or more times the normal value on one or more occasions. This was attributable to the noncardiac fraction of CK. Muscle pain or dysfunction usually was not reported .<br/>Concomitant Lipid-Lowering Therapy: In controlled clinical studies in which simvastatin was administered concomitantly with cholestyramine, no adverse reactions peculiar to this concomitant treatment were observed. The adverse reactions that occurred were limited to those reported previously with simvastatin or cholestyramine. The combined use of simvastatin at doses exceeding 10 mg/day with gemfibrozil should be avoided .<br/>Adolescent Patients (ages 10-17 years): In a 48-week, controlled study in adolescent boys and girls who were at least 1 year post-menarche, 10-17 years of age with heterozygous familial hypercholesterolemia (n=175), the safety and tolerability profile of the group treated with simvastatin (10-40 mg daily) was generally similar to that of the group treated with placebo, with the most common adverse experiences observed in both groups being upper respiratory infection, headache, abdominal pain, and nausea . | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:indicatio... | Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). In patients with CHD or at high risk of CHD, Simvastatin Orally Disintegrating Tablets can be started simultaneously with diet.<br/>Reductions in Risk of CHD Mortality and Cardiovascular Events: In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, Simvastatin Orally Disintegrating Tablets are indicated to:<br/>Patients with Hypercholesterolemia Requiring Modifications of Lipid Profiles: Simvastatin Orally Disintegrating Tablets are indicated to:<br/>Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH): Simvastatin Orally Disintegrating Tablets are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolemia, if after an adequate trial of diet therapy the following findings are present: The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C<130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined.<br/>General Recommendations: Prior to initiating therapy with simvastatin, secondary causes for hypercholesterolemia (e.g., hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = total-C���[(0.20��TG) + HDL-C] For TG levels>400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, Simvastatin Orally Disintegrating Tablets are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient's response to therapy. The NCEP Treatment Guidelines are summarized in Table 6: After the LDL-C goal has been achieved, if the TG is still���200 mg/dL, non-HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge. The NCEP classification of cholesterol levels in pediatric patients with a familial history of either hypercholesterolemia or premature cardiovascular disease is summarized in Table 7. Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Simvastatin Orally Disintegrating Tablets are indicated to reduce elevated LDL-C and TG levels in patients with Type IIb hyperlipidemia (where hypercholesterolemia is the major abnormality). However, it has not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:798 | dailymed-instance:name | Simvastatin | lld:dailymed |
| http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:798 | lld:dailymed |
| diseasome-diseases:116 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:764 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:634 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2839 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:319 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2175 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:561 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:1283 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:1092 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:3977 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:949 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2701 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:3639 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:3730 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:51 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:710 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:307 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:1043 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:1507 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2129 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:3045 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:3166 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:3867 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:270 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:102 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:535 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:560 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:592 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:604 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:674 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:1154 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:1155 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:1368 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:1471 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2010 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2210 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2652 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2695 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2760 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2794 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:2951 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:3044 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:4095 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |
| diseasome-diseases:4097 | diseasome-instance:possible... | dailymed-drugs:798 | lld:diseasome |